GlaxoSmithKline PLC’s announcement April 2 that it has stopped a Phase III trial of its MAGE-A3 cancer vaccine in non-small cell lung cancer patients wasn’t a surprise, but as the third piece of disappointing R&D news for the company in one week, it does put more pressure on GSK to deliver on its recent drug launches.
GSK already reported disappointing data on MAGE-A3, most recently in March when the Phase III NSCLC trial failed to demonstrate an efficacy benefit in patients over placebo, but also in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?